Xilio Therapeutics (XLO) Total Non-Current Liabilities (2020 - 2026)

Xilio Therapeutics has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $64.7 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $64.7 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $64.7 million (changed N/A YoY), and the FY2025 annual result was $89.9 million, changed N/A from the prior year.
• Total Non-Current Liabilities came in at $64.7 million for Q1 2026 at Xilio Therapeutics, down from $89.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $89.9 million in Q4 2025 to a low of $25.0 million in Q2 2023.
• The 4-year median for Total Non-Current Liabilities is $33.7 million (2022), against an average of $51.1 million.
• Across the five-year window, Total Non-Current Liabilities increased 2.95% in 2022 and dropped 26.17% in 2023, its largest moves.
• Xilio Therapeutics' Total Non-Current Liabilities stood at $33.5 million in 2022, then fell by 25.39% to $25.0 million in 2023, then soared by 259.77% to $89.9 million in 2025, then declined by 28.01% to $64.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $64.7 million (Q1 2026), $89.9 million (Q4 2025), and $87.9 million (Q3 2025), per Business Quant data.